Aadi bioscience transforms with in-licensing of novel adc portfolio, $100 million sale of fyarro® and $100 million pipe financing

Aadi enters into exclusive license for three-asset adc portfolio developed through a collaboration between wuxi biologics and hangzhou dac   aadi enters agreement to sell fyarro® and associated infrastructure to kaken pharmaceutical for $100m; announces pipe financing of $100m cumulative capital expected to fund operations into late 2028, including anticipated clinical data for the adc portfolio co-founder and former ceo of profoundbio, baiteng zhao, appointed to aadi board of directors aadi to hold webcast and conference call on december 20 at 8:00 am est los angeles , dec. 19, 2024 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi) today announced it has entered into an exclusive license agreement for development and global commercialization of a three-asset portfolio of preclinical, next-wave antibody-drug conjugates (adcs), in collaboration with wuxi biologics (2269.hk), a leading global contract research, development and manufacturing organization (crdmo), and hangzhou dac biotechnology co., ltd. (hangzhou dac), a global leader in adc innovation.
AADI Ratings Summary
AADI Quant Ranking